[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100406701":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":38,"centralContacts":43,"locations":53,"responsibleParty":75,"collaborators":78,"id":84,"slug":29,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":29,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":29,"overallStatus":55,"whyStopped":29,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"University of Virginia","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Exercise Alone","EXPERIMENTAL","24 weeks of treatment",[13],"Other: Exercise training",{"label":15,"type":10,"description":11,"interventionNames":16},"Liraglutide Alone",[17],"Drug: Liraglutide",{"label":19,"type":10,"description":20,"interventionNames":21},"Exercise + Liraglutide","24 weeks f treatment",[22],"Drug: Liraglutide + Exercise training",[24,30,34],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Liraglutide","24 weeks of Liraglutide",[15],null,{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Exercise training","24 weeks of Exercise training",[9],{"type":25,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"Liraglutide + Exercise training","24 weeks of Liraglutide + Exercise training",[19],[39],{"name":40,"affiliation":41,"role":42},"Zhenqi Liu, MD","Division of Endocrinology and Metabolism, University of Virginia","PRINCIPAL_INVESTIGATOR",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":29,"email":48},"Lee Hartline, MEd","CONTACT","434-924-5247","lmh9d@virginia.edu",{"name":50,"role":46,"phone":51,"phoneExt":29,"email":52},"Linda Jahn, MEd","434-924-1134","las6e@virginia.edu",[54],{"facility":5,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"RECRUITING","Charlottesville","Virginia","22906","United States","US",{"type":62,"coordinates":63},"Point",[64,65],-78.47668,38.02931,{"lat":65,"lon":64},[68,71],{"name":40,"role":46,"phone":69,"phoneExt":29,"email":70},"434-243-2603","zl3e@virginia.edu",{"name":72,"role":46,"phone":73,"phoneExt":29,"email":74},"Eugene Barrett, MD, PhD","434-924-1175","ejb8x@virginia.edu",{"type":42,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Zhenqi Liu","Professor, Division of Endocrinology and Metabolism",[79,82],{"name":80,"class":81},"National Institutes of Health (NIH)","NIH",{"name":83,"class":81},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","100406701",false,"NCT04575844","Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome","ZQL008","Inclusion Criteria:\n\n* Male or female ≥21 and ≤60 years old.\n* Body mass index \\>25 and ≤35 kg\u002Fm2 and is weight stable (\\\u003C5 kg weight change in the past 6 months). BMI is limited to ≤35 kg\u002Fm2 for easier vascular access and cardiac imaging.\n* Meet 3 of 5 National Cholesterol Education Program Adult Treatment Panel III Metabolic Syndrome criteria:\n\n  * Increased waist circumference (≥102 cm in men; ≥88 cm in women)\n  * Elevated triglycerides (≥150 mg\u002Fdl)\n  * Reduced HDL-cholesterol (\\\u003C40mg\u002Fdl in men, \\\u003C50 mg\u002Fdl in women)\n  * High blood pressure (≥130 mmHg systolic or ≥85mmHg diastolic)\n  * Elevated fasting glucose (≥100 mg\u002Fdl)\n  * Subject may participate if on the following drugs, provided the drug doses have been stable for at least 3 months.\n  * Ace inhibitor\n  * ARB\n  * HMG CoA reductase inhibitor\n  * Beta blocker\n  * Calcium channel blockers\n  * Alpha-adrenergic antagonist\n  * Statin\n\nExclusion Criteria:\n\n* A diagnosis of any type of diabetes or history of diabetes medication use\n* Recently active (\\>20 min of moderate\u002Fhigh intensity exercise, 2 times\u002Fweek)\n* Subjects who are smokers or who have quit smoking \\\u003C5 years\n* Subjects with hypertriglyceridemia (\\>400 mg\u002Fdl) or hypercholesterolemia (\\>260 mg\u002Fdl)\n* Subjects with BP\\>160\u002F90\n* Subjects with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or malignancy\n* Pregnant (as evidenced by positive pregnancy test) or nursing women\n* Subjects with contraindications to participation in an exercise training program\n* Allergic to perflutren\n* A prior use of Liraglutide",true,"ALL","21 Years","60 Years",{"count":95,"type":96},80,"ESTIMATED","INTERVENTIONAL",[99],"PHASE4","The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume, improves vascular function of the conduit vessels, and enhances insulin's metabolic action in humans with Metabolic Syndrome. Subjects will be randomized to one of the 4 groups: control, exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 24 weeks of intervention.",[102],"Metabolic Syndrome","2026-05-01",{"date":105,"type":106},"2026-05-06","ACTUAL",{"date":108,"type":106},"2020-11-01",{"date":110,"type":96},"2027-04-30",{"name":5,"class":6},1]